Drug intelligence / Profile preview

KJ-101

Development stage: Phase 2
Lead developer: Kisoji Biotechnology
Modality: Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Topical, Injection

Overview

KJ-101 is a trispecific antibody targeting CD47, D2 receptor, and PD-1. It is developed by Kisoji Biotechnology, Inc., and Shanghai Bao Pharmaceuticals. The drug is primarily aimed at treating neoplasms and immune system diseases, with active indications in multiple myeloma and small cell lung cancer. Additionally, Shanghai Bao Pharmaceuticals is developing KJ-101 for wound and injury treatments.

Brand names: KJ101KJ-101KJ 101
Other names: KJ101KJ-101KJ 101

Targets

CD47 (Cluster of Differentiation 47)DRD2 (Dopamine D2 Receptor)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on KJ-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KJ-101.

Explore the full profile